Novo Integrated Sciences, Inc. provided revenue guidance for the third quarter of fiscal year 2022. For the quarter, the company's revenue is expected to be in the range of $13.4 million to $13.9 million, an increase of approximately 367% to 384%, as compared to the second quarter of fiscal year 2022, and an increase of approximately 463% to 484%, as compared to the third quarter of fiscal 2021. The company's strong revenue performance in the third quarter was driven primarily by an increase in both proprietary and outsourced product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4774 USD | +9.26% | -17.50% | -41.85% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.85% | 8.32M | |
+18.63% | 85.14B | |
-27.41% | 72.06B | |
+2.75% | 27.07B | |
-9.66% | 17.43B | |
-1.96% | 16.98B | |
+3.96% | 16.02B | |
+7.75% | 13.87B | |
+72.83% | 13.06B | |
+72.50% | 12.79B |
- Stock Market
- Equities
- NVOS Stock
- News Novo Integrated Sciences, Inc.
- Novo Integrated Sciences, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2022